Aadi clinches first FDA nod for ultrarare sarcoma drug Fyarro

Aadi Bioscience's new cancer med Fyarro boasts two firsts: It's the California-based company's first commercial product, and it's the first treatment to take aim at an ultrarare and aggressive form of sarcoma.

The FDA on Tuesday approved Fyarro, also known as sirolimus protein-bound particles for injectable suspension, in adults with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).